GABAA signalling is involved in N/OFQ anxiolytic-like effects but not in nocistatin anxiogenic-like action as evaluated in the mouse elevated plus maze

Peptides

Volumn 29, Issue 8, 2008, Pages 1404-1412

  Gavioli, Elaine C ^a   Duarte, Filipe S ^b   Guerrini, Remo ^c   Calo, Girolamo ^d   Rae, Giles A ^b   M De Lima, Thereza C ^b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF FERRARA   (Italy)

^d Neuroscience Center   (Italy)

Author keywords

Anxiety; GABAA receptor ligands; Mouse; Nociceptin orphanin FQ; Nocistatin; NOP receptor

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DIAZEPAM; DIENPAX; FLUMAZENIL; NOCICEPTIN; NOCISTATIN; PENTETRAZOLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEDATION; SIGNAL TRANSDUCTION; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; LIGANDS; MALE; MAZE LEARNING; MICE; OPIOID PEPTIDES; RECEPTORS, GABA-A; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

MUS;

EID: 47649119592     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.04.004     Document Type: Article

References (54)

1. 2+] and cell excitability in primary cultures of rat cortical neurons. Neuropharmacology 47 (2004) 873-883
2. Boom A., Mollereau C., Meunier J.C., Vassart G., Parmentier M., Vanderhaeghen J.J., et al. Distribution of the nociceptin and nocistatin precursor transcript in the mouse central nervous system. Neuroscience 91 (1999) 991-1007
3. Chopin P., and Briley M. The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology (Berl) 110 (1993) 409-414
4. Ciccocioppo R., Panocka I., Polidori C., Regoli D., and Massi M. Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology 141 (1999) 220-224
5. Cox B.M., Chavkin C., Christie M.J., Civelli O., Evans C., Hamon M.D., et al. Opioid receptors. In: Girdlestone D. (Ed). The IUPHAR compendium of receptor characterization and classification (2000), IUPHAR Media Ltd., London 321-333
6. Dalvi A., and Rodgers R.J. Behavioral effects of diazepam in the murine plus-maze: flumazenil antagonism of enhanced head dipping but not the disinhibition of open-arm avoidance. Pharmacol Biochem Behav 62 (1999) 727-734
7. Devine D.P., Taylor L., Reinscheid R.K., Monsma Jr. F.J., Civelli O., and Akil H. The novel peptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res 727 (1996) 225-229
8. Fernandez-Guasti A., and Lopez-Rubalcava C. Modification of the anxiolytic action of 5-HT1A compounds by GABA-benzodiazepine agents in rats. Pharmacol Biochem Behav 60 (1998) 27-32
9. Fernandez F., Misilmeri M.A., Felger J.C., and Devine D.P. Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety. Neuropsychopharmacology 29 1 (2004) 59-71
10. Ferris P., Seward E., and Dawson G.R. Interactions between LY354740, a group II metabotropic agonist and the GABA (A)-benzodiazepine receptor complex in the rat elevated plus-maze. J Psychopharmacol 15 (2001) 76-82
11. Florin S., Suaudeau C., Meunier J.C., and Costentin J. Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur J Pharmacol 317 (1996) 9-13
12. Florin S., Meunier J., and Costentin J. Autoradiographic localization of [3H]nociceptin binding sites in the rat brain. Brain Res 880 (2000) 11-16
13. Gavioli E.C., and Calo G. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands. Naunyn Schmiedebergs Arch Pharmacol 372 (2006) 319-330
14. Gavioli E.C., Rae G.A., Calo G., Guerrini R., and De Lima T.C. Central injections of nocistatin or its C-terminal hexapeptide exert anxiogenic-like effect on behaviour of mice in the plus-maze test. Br J Pharmacol 136 (2002) 764-772
15. Golombek D.A., Martini M., and Cardinali D.P. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol 237 (1993) 231-236
16. Green M.K., Barbieri E.V., Brown B.D., Chen K.W., and Devine D.P. Roles of the bed nucleus of stria terminalis and of the amygdala in N/OFQ-mediated anxiety and HPA axis activation. Neuropeptides 41 6 (2007) 399-410
17. Griebel G., Perrault G., and Sanger D.J. Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res 836 (1999) 221-224
18. Guerrini R., Calo G., Rizzi A., Bianchi C., Lazarus L.H., Salvadori S., et al. Address and message sequences for the nociceptin receptor: a structure- activity study of nociceptin-(1-13)-peptide amide. J Med Chem 40 (1997) 1789-1793
19. Hiramatsu M., and Inoue K. Effects of nocistatin on nociceptin-induced impairment of learning and memory in mice. Eur J Pharmacol 367 (1999) 151-155
20. Hiramatsu M., and Inoue K. Nociceptin/orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice. Br J Pharmacol 127 (1999) 655-660
21. Ikeda K., Watanabe M., Ichikawa T., Kobayashi T., Yano R., and Kumanishi T. Distribution of prepro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems. J Comp Neurol 399 (1998) 139-151
22. Jenck F., Moreau J.L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma Jr. F.J., et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci U S A 94 (1997) 14854-14858
23. Jenck F., Wichmann J., Dautzenberg F.M., Moreau J.L., Ouagazzal A.M., Martin J.R., et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci U S A 97 (2000) 4938-4943
24. Kamei J., Matsunawa Y., Miyata S., Tanaka S., and Saitoh A. Effects of nociceptin on the exploratory behavior of mice in the hole-board test. Eur J Pharmacol 489 (2004) 77-87
25. Kulkarni S.K., and Sharma K. Alprazolam modifies animal behaviour on elevated plus-maze. Indian J Exp Biol 31 (1993) 908-911
26. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16 (1986) 355-357
27. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92 (1987) 180-185
28. Lydiard R.B. The role of GABA in anxiety disorders. J Clin Psychiatry 3 (2003) 21-27
29. Meis S., and Pape H.C. Control of glutamate and GABA release by nociceptin/orphanin FQ in the rat lateral amygdala. J Physiol 532 (2001) 701-712
30. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
31. Murphy N.P., Lee Y., and Maidment N.T. Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res 832 (1999) 168-170
32. Nakagawa T., Kaneko M., Inamura S., and Satoh M. Intracerebroventricular administration of nocistatin reduces inflammatory hyperalgesia in rats. Neurosci Lett 265 (1999) 64-66
33. Neal Jr. C.R., Mansour A., Reinscheid R., Nothacker H.P., Civelli O., Akil H., et al. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol 412 (1999) 563-605
34. Nicol B., Lambert D.G., Rowbotham D.J., Okuda-Ashitaka E., Ito S., Smart D., et al. Nocistatin reverses nociceptin inhibition of glutamate release from rat brain slices. Eur J Pharmacol 356 (1998) R1-R3
35. Nutt D.J., and Malizia A.L. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179 (2001) 390-396
36. O'Neill A.B., and Brioni J.D. Benzodiazepine receptor mediation of the anxiolytic-like effect of (-)-nicotine in mice. Pharmacol Biochem Behav 49 (1994) 755-757
37. Okuda-Ashitaka E., Minami T., Tachibana S., Yoshihara Y., Nishiuchi Y., Kimura T., et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 392 (1998) 286-289
38. Okuda-Ashitaka E., and Ito S. Nocistatin: a novel neuropeptide encoded by the gene for the nociceptin/orphanin FQ precursor. Peptides 21 (2000) 1101-1109
39. Olszewski P.K., Shaw T.J., Grace M.K., Billington C.J., and Levine A.S. Nocistatin inhibits food intake in rats. Brain Res 872 (2000) 181-187
40. Pierrefiche G., Zerbib R., and Laborit H. Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors. Res Commun Chem Pathol Pharmacol 82 (1993) 131-142
41. Pomonis J.D., Billington C.J., and Levine A.S. Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. Neuroreport 8 (1996) 369-371
42. Przegalinski E., Tatarczynska E., and Chojnacka-Wojcik E. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 39 (2000) 1858-1864
43. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
44. Roberto M., and Siggins G.R. Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdale. Proc Natl Acad Sci U S A 103 (2006) 9715-9720
45. Rodgers R.J., Cao B.J., Dalvi A., and Holmes A. Animal models of anxiety: an ethological perspective. Braz J Med Biol Res 30 (1997) 289-304
46. Rodi D., Zucchini S., Simonato M., Cifani C., Massi M., and Polidori C. Functional antagonism between nociceptin/orphanin FQ (N/OFQ) and corticotropin-releasing factor (CRF) in the rat brain: evidence for involvement of the bed nucleus of the stria terminalis. Psychopharmacology (Berl) 196 4 (2008) 523-531
47. Sandin J., Georgieva J., Schott P.A., Ogren S.O., and Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 9 (1997) 194-197
48. Sbrenna S., Marti M., Morari M., Calo G., Guerrini R., Beani L., et al. L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors. J Pharmacol Exp Ther 291 (1999) 1365-1371
49. Sharma A.C., and Kulkarni S.K. Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats. Indian J Exp Biol 31 (1993) 191-193
50. Sun R.Q., Zhao C.S., Wang H.J., Jing Z., Wang W., Yang K., et al. Nocistatin, a peptide reversing acute and chronic morphine tolerance. Neuroreport 12 (2001) 1789-1792
51. Tajalli S., Jonaidi H., Abbasnejad M., and Denbow D.M. Interaction between nociceptin/orphanin FQ (N/OFQ) and GABA in response to feeding. Physiol Behav 89 (2006) 410-413
52. Varty G.B., Hyde L.A., Hodgson R.A., Lu S.X., McCool M.F., Kazdoba T.M., et al. Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species. Psychopharmacology (Berl) 182 (2005) 132-143
53. Vaughan C.W., Ingram S.L., and Christie M.J. Actions of the ORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. J Neurosci 17 (1997) 996-1003
54. Vitale G., Arletti R., Ruggieri V., Cifani C., and Massi M. Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats. Peptides 27 (2006) 2193-2200